Roflumilast 0.05% sNDA submitted to FDA for atopic dermatitis in children 2 to 5 years

Published Date: 19 Dec 2024

Arcutis seeks FDA approval for roflumilast cream 0.05% (ZORVYE) to treat mild to moderate atopic dermatitis in children 2 to 5 years.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

2.

FDA approves Blenrep for relapsed or refractory multiple myeloma

3.

X-ray and radar technology combined to reduce cancer screening risks

4.

Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.

5.

Researchers discuss HER2-low and HER2-zero in breast cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot